Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Berekméri, Anna; Mahmood, Farrouq; Wittmann, Miriam; Helliwell, Philip S.

doi:10.1080/1744666x.2018.1512404

Cited by 103 publications

(89 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Эффект большинства цитокинов опосредован сигнальным путем JAK/STAT (Signal Transducer and Activator of Transcription). JAK -группа ферментов, обеспечивающих функцию «включения» и «выключения» сигнала, передаваемого цитокином, эти ферменты рассматриваются в качестве терапевтической мишени при необходимости подавления гиперактивных иммунных реакций [14].…”

unclassified

“…Основное действие ТОФА -ингибирование ферментов JAK1/3, однако в более высоких дозах он может также оказывать определенный эффект на JAK2-опосредованную передачу сигнала, которая играет важную роль в регуляции гемопоэза. Именно низкой активностью ТОФА в отношении JAK2 объясняются меньшие, чем при использовании других ингибиторов JAK, частота и выраженность цитопении [12,14]. JAK1 и JAK3 также являются важными сигнальными молекулами.…”

unclassified

“…Считается, что терапевтический эффект ТОФА в отношении очаговой алопеции достигается главным образом благодаря ингибированию активности CD8+ Т-лимфоцитов, опосредованно повреждающих волосяной фолликул за счет действия ИЛ15 и ИФНγ [16]. В этом контексте важнейшую роль играет ИЛ21, поскольку этот цитокин продуцируется преимущественно CD4+ T-лимфоцитами и, по-видимому, необходим для реализации устойчивой эффекторной активности CD8+ T-лимфоцитов [14].…”

unclassified

“…Наиболее часто встречались назофарингит, инфекции верхних дыхательных путей и головная боль. Полученные данные сопоставимы с результатами оценки безопасности в OPAL Beyond, в котором на фоне применения ТОФА в дозе 10 мг отмечалась более высокая частота НЯ и самостоятельной отмены препарата [14].…”

unclassified

“…В OPAL Broaden выявлено 3 эпизода тяжелых инфекционных осложнений в течение 12 мес (грипп, острый аппендицит и пневмония) в группе ТОФА и 1 эпизод тяжелой инфекции в группе АДА (простой герпес и стрепто-кокковая пиодермия). В обоих исследованиях не было тяжелых инфекционных осложнений в группах плацебо [14].…”

unclassified

See 4 more Smart Citations

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis

Коротаева¹,

Логинова²

2019

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The paper reviews of the data available in the literature on the clinical efficacy and safety of tofacitinib (TOFA) in the treatment of psoriatic arthritis (PsA). It considers the mechanism of action of TOFA, which is mainly in the selective inhibition of signal transmission due to its effect on the activity of JAK3 and/or JAK1, the enzymes that ensure the function of turning on and turning off the signals transmitted by cytokines. TOFA is noted to directly or indirectly act on a wide range of a number of molecules that play an important role in the pathogenesis of PsA.The paper analyzes the current data on the clinical efficacy of TOFA in treating PsA, which have been obtained in the 12-month OPAL Broaden study including patients with PsA and an inadequate response to synthetic disease-modifying anti-rheumatic drugs and in the 6-month OPAL Beyond study enrolling those with PsA and an inadequate response to tumor necrosis factor-α (TNF-α) inhibitors. It is noted that the results of these studies confirmed the efficacy of the drug in treating PsA not only according to the data of objective (medical) monitoring, but also to the subjective characteristics of pain, to the global assessment of disease activity, fatigue, as well as the mental and physical components of the SF-36 quality of life questionnaire.It is concluded that the current findings allow JAK inhibitors to be recommended as a new pathogenetically sound approach to treating PsA and suggest that TOFA has benefits in managing patients unresponsive to therapy with TNF-α inhibitors.

show abstract

unclassified

See 3 more Smart Citations

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis

Коротаева¹,

Логинова²

2019

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Psoriatic arthritis—What we know now?

Shah

Koschitzky

Khattri

2021

Dermatological Reviews

View full text Add to dashboard Cite

Introduction: Over the past decade, our understanding of psoriatic arthritis (PsA) as a chronic inflammatory condition with a heterogenous manifestation has vastly improved. A better understanding of pathophysiology, susceptibility, clinical features, and treatment have all warranted a comprehensive and organized review of this musculoskeletal disorder which continues to affect a growing population of the western world along with psoriasis patients.Methods: Relevant articles on PsA were retrieved through a selective search on PubMed.Discussion: By acknowledging the present state of diagnostic methods and subsequent treatment strategies, clinicians will be more equipped to identify and treat this condition while also encouraging the importance of screening those who may be susceptible based on immune, environmental, and genetic factors. This article reviews the current knowledge of PsA and addresses the areas for future research.

show abstract

JAK Inhibitors in Solid Organ Transplantation

Assadiasl

Mojtahedi

Nicknam

2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Janus kinase (JAK) inhibitors are a novel group of immunosuppressive drugs approved to treat certain rheumatic and allergic disorders; however, their efficacy in the regulation of alloimmune responses after solid organ transplantation has not yet been elucidated. In the present review, we have summarized the results of in vitro, in vivo, experimental, and clinical trial studies about the efficacy and safety of JAK inhibitors in improving allograft survival in solid organ transplantations, including kidney, heart, lung, and liver transplants. Moreover, reports on administering JAK inhibitors to steroid‐resistant patients with graft versus host disease (GvHD) after solid organ transplantation have been reviewed. Overall findings are suggestive of a beneficial role for JAK inhibitors in organ transplantation: for example, they have been shown to improve allograft function, reduce the rate and score of acute rejection, downregulate the expression of proinflammatory cytokines and adhesion molecules, and decrease oxidative stress. However, the adverse effects of these drugs, in particular bone marrow suppression and infection, remain an obstacle.

show abstract

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Cited by 103 publications

References 27 publications

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis

Psoriatic arthritis—What we know now?

JAK Inhibitors in Solid Organ Transplantation

Contact Info

Product

Resources

About